Routine vaccination in HIV-infected adults

Infectious Diseases in Clinical Practice

Volumn 16, Issue 2, 2008, Pages 85-93

  Landrum, Michael L ^a   Dolan, Matthew J ^b  

^a Department of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; VACCINATION;

EID: 40949135156     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31815c5e6e     Document Type: Review

References (129)

1. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39(5):609-629.
2. Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38:1478-1484.
3. Dworkin MS, Ward JW, Hanson DL, et al. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794-800.
4. Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine. 2006;24:272-279.
5. Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005;19:1473-1479.
6. Fonseca MO, Pang LW, Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard to a double dose. Vaccine. 2005;23:2902-2908.
7. Kroon FP, van Dissel JT, Ravensbergen E, et al. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2001;19:886-894.
8. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis. 1996;173:83-90.
9. King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181:725-728.
10. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18(26):3040-3049.
11. Brichacek B, Swindells S, Janoff EN, et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis. 1996;174:1191-1199.
12. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine. 2002;20:3720-3724.
13. Tasker SA, Wallace MR, Rubins JB, et al. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis. 2002;34:813-821.
14. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine. 2002;20:545-553.
15. Cheeseman SH, Davaro RE, Ellison RT. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med. 1996;334:1272.
16. Fuller JD, Craven DE, Steger KA, et al. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis. 1999;28:541-547.
17. Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. Clin Infect Dis. 2000;181:522-531.
18. Macias J, Pineda JA, Leal M, et al. HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination. Eur J Clin Microbiol Infect Dis. 2001;20:46-48.
19. Glesby MJ, Hoover DR, Farzadegan H, et al. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis. 1996;174:1332-1336.
20. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997;11:1013-1021.
21. Tasker SA, O'Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine. 1998;16:1039-1042.
22. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001;65:644-648.
23. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191:1442-1450.
24. Kolber MA, Gabr AH, De La Rosa A, et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS. 2002;16:537-542.
25. Pinto LA, Blazevic V, Anderson SA, et al. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J Infect Dis. 2001;183(7):1000-1009.
26. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;86:1082-1089.
27. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182:1727-1737.
28. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-1230.
29. Crouch RB. Editorial response: influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis. 1999;28:548-551.
30. Sullivan PS, Hanson DL, Dworkin MS, et al. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS. 2000;14:2781-2785.
31. Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med. 1998;129(2):104-106.
32. Talbot EA, Perkins MD, Silva SFM, et al. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis. 1997;24:1139-1146.
33. Edwards KM, Kernodle DS. Possible hazards of routine Bacillus Calmette-Guerin immunization with human immunodeficiency virus infected children. Pediatr Infect Dis J. 1996;15:836-838.
34. Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics. 2001;108:e39-e42.
35. Redfield RR, Wright DG, James WD, et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:67-676.
36. Receveur MC, Thiebaut R, Vedy S, et al. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of two cases. Clin Infect Dis. 2000;31:e7-e8.
37. Goujon C, Tohr M, Feuillie V, et al. Good tolerance and efficacy of yellow fever vaccine among subject carriers of human immunodeficiency virus. Program and abstracts of the 4th International Conference on Travel Medicine. Geneva, Switzerland: International Society of Travel Medicine/World Health Organization; 1995:63.
38. Wallace MR, Hooper DG, Graves SJ, et al. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine. 1994;12(13):1222-1224.
39. Sprauer MA, Markowitz LE, Nicholson JK, et al. Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. J Acquir Immune Defic Syndr. 1993;6(9):1013-1016.
40. Tasker SA, Schnepf GA, Lim M, et al. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis. 2004;38:1320-1322.
41. Armenian SH, Han JY, Dunaway TM, et al. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2006;25:368-370.
42. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310.
43. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis. 2006;194:247-255.
44. Centers for Disease Control and Prevention. Recommended adult immunization schedule: United States, October 2006-September 2007. MMWR. 2006;55:Q1-Q4.
45. Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR. 2001;50:1-25.
46. Centers for Disease Control and Prevention. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR. 2003;52:1-16.
47. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571-577.
48. Shire NJ, Rouster SD, Rajicic N, et al. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36:869-875.
49. Thomas DL, Cannon RO, Shapiro CN, et al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis. 1994;169:990-995.
50. Tien PC, Kovacs A, Bacchetti P, et al. Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the women's interagency HIV study. Clin Infect Dis. 2004;39:1363-1370.
51. Sinicco A, Raiteri R, Sciandra M. Co-infected and super-infection of hepatitis B virus in patients infected with HIV: no evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29:111-115.
52. Sheng W, Chen M, Hsieh S, et al. Impact of chronic hepatitis B virus infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38:1471-1477.
53. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29(4):1306-1310.
54. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-1926.
55. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003;23:125-136.
56. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS. 2005;19:221-240.
57. Gilson RJC, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597-606.
58. Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29(1):41-48.
59. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14(18):2895-2902.
60. Sulkowski M, Thomas DL, Mehta SH, et al. Hepatoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology. 2002;35(1):182-189.
61. Sulkowski M, Thomas DL, Chaisson RE, et al. Hepatoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74-80.
62. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis. 2004;38:s49-s55.
63. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18(17):2277-2284.
64. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR. 2002;51(RR-8):1-40.
65. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. 2005;54:1-30.
66. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR. 2006;55:1-25.
67. Collier AC, Corey L, Murphy VL, et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988;109:101-105.
68. Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable HIV plasma RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41:1045-1048.
69. Quaglio G, Talamini G, Lugoboni F, et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction. 2002;97:985-992.
70. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000;18:1161-1165.
71. Wong EK, Bodsworth NJ, Slade MA, et al. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS. 1996;7:490-494.
72. Keet IP, van Doornum G, Safary A, et al. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 1992;6:509-510.
73. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS. 1994;8:558-559.
74. Kim HN, Harrington RD, Van Rompaey SE, et al. Predictors of lack of response to hepatitis B vaccination in HIV-infected patients. 44th Annual Meeting of the Infectious Diseases Society of America, 12-15 October, Toronto, Ontario, Canada. Abstract 1199. 2006.
75. Wang C, Tang J, Song W, et al. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004;39:978-988.
76. Mannucci PM, Zanetti AR, Gringeri A, et al. Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med. 1989;149:1333-1337.
77. Verthelyi D, Wang VW, Lifson JD, et al. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS. 2004;18:1003-1008.
78. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
79. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209-214.
80. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 1991;163:454-459.
81. Hadler SC, Coleman JC, O'Malley PM, et al. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men in viral hepatitis and liver disease. In: Hollinger FB, Lemon SM, Margolis H, eds. Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease - Contemporary Issues and Future Prospects. Baltimore: Williams and Wilkins; 1991.
82. Landrum ML, Hullsiek KH, Ganesan A, et al. The clinical efficacy of hepatitis B vaccine in HIV-1 infected individuals. Final Program and Abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA. Arlington, VA: Infectious Diseases Society of America; 2007.
83. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis. 2005;191:2038-2045.
84. Jordano Q, Falco V, Almirante B, et al. Invasive Pneumococcal Disease in Patients Infected with HIV: Still a Threat in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis. 2004;38:1623-1628.
85. Tacconelli E, Tumbarello M, de Gaetano K, et al. Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. Clin Infect Dis. 1998;27:901-902.
86. Barry PM, Zetola N, Keruly JC, et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS. 2006;20:437-444.
87. Nuorti JP, Butler JC, Gelling L, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med. 2000;132:182-190.
88. Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis. 1990;162:1012-1017.
89. Hibbs JR, Douglas JM, Judson FN, et al. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with Pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis. 1997;25:195-199.
90. Fry AM, Facklam RR, Whitney CG, et al. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States. J Infect Dis. 2003;188:643-652.
91. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005;165:1533-1540.
92. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 1997;46:1-24.
93. Falco V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine. 2006;24:2567-2574.
94. Glaser JB, Volpe S, Aguirre A, et al. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis. 1991;164:761-764.
95. Janoff EN, Fasching C, Ojoo JC, et al. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis. 1997;175:975-978.
96. Nielsen H, Kvinesdal B, Benfield TL, et al. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand Infect Dis. 1998;30:597-601.
97. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003;37:438-447.
98. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis. 1992;165:553-556.
99. Kroon FP, van Dissel JT, Ravensbergen E, et al. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 2000;18:524-530.
100. Janoff EN, Douglas JM, Gabriel M, et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with Human Immunodeficiency Virus Type 1. J Infect Dis. 1988;158:983-990.
101. Huang KL, Ruben FL, Rinaldo CR, et al. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA. 1987;257:2047-2050.
102. Rodriguez-Barradas MC, Groover JE, Lacke CE, et al. IgG antibody to pneumococcal capsular polysaccharide in Human Immunodeficiency Virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis. 1996;173:1347-1353.
103. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000;160:2633-2638.
104. Gebo KA, Moore RD, Keruly JC, et al. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:857-862.
105. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106-2111.
106. Lopez-Palomo C, Martin-Zamorano M, Benitez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol. 2004;72:517-524.
107. French N, Moore M, Haikala R, et al. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis. 2004;190:707-712.
108. Musher DM, Phan HM, Watson DA, et al. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J Infect Dis. 2000;182:158-167.
109. Subramaniam KS, Segal R, Lyles RH, et al. Qualitative change in antibody responses of Human Immunodeficiency Virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis. 2003;187:758-768.
110. Radwan HM, Cheeseman SH, Lai KK, et al. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis. 2000;31:604-606.
111. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32(12):1784-1791.
112. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2006;55(RR 10):1-42.
113. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis. 2006;6:138-143.
114. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(2):167-173.
115. Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(6):430-433.
116. + T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:1197-1203.
117. Overton ET, Nurutdinova D, Sungkanuparph S, et al. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat. 2007;14:189-193.
118. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS. 2005;19:1702-1704.
119. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat. 2006;13:81-86.
120. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis. 2004;39:1207-1213.
121. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943.
122. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
123. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2007;56:1-24.
124. Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive mena and women. J Natl Cancer Inst Monogr. 1998;23:15-20.
125. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001;183:383-391.
126. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177:361-367.
127. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91:226-236.
128. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursers among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;183:453-459.
129. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-2145.